Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
688526 Wuhan Keqian Biology Co.,Ltd
25.990
+0.160+0.62%
YOY
Do not show
Hide blank lines
(Q9)2022/09/30(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31
Per Share Indicator
Net Asset Per Share
13.43% 7.2217 12.86% 6.941 12.71% 6.9749 16.39% 6.7797
Basic Earning Per Share
-26.51% 0.61 -45.16% 0.34 -44.44% 0.2 6.03% 1.23
Diluted  Earning Per Share
-26.51% 0.61 -45.16% 0.34 -44.44% 0.2 6.03% 1.23
Earning Per Share
-26.64% 0.6087 -44.41% 0.3421 -46.30% 0.1951 27.41% 1.227
Diluted Earning Per Share(TTM)
-8.99% 1.0057 -19.51% 0.9539 -6.05% 1.059 27.41% 1.227
Capital Surplus Funds Per Share
1.86% 2.4211 1.34% 2.4056 0.95% 2.3964 0.95% 2.3964
Undivided Profit Per Share
26.37% 3.3119 26.63% 3.0479 26.42% 3.091 39.11% 2.8958
Operating Cash Flow Per Share
-30.19% 0.7112 -33.37% 0.3989 -57.30% 0.2287 32.74% 1.1422
Enterprise FCF Per Share
-52.89% 0.2578 338.37% 1.2511 -83.82% 0.0662 -613.09% -0.7214
Shareholder FCF Per Share
-119.24% -0.0606 410.68% 1.0183 -98.26% 0.006 -8,953.04% -1.0181
EBIT Per Share
-30.73% 0.5946 -50.39% 0.3212 -51.15% 0.1905 22.23% 1.2795
Profitability
ROE Weighted
-36.16% 8.670% -51.14% 4.940% -53.06% 2.840% -28.87% 19.560%
ROE
-35.31% 8.430% -50.74% 4.928% -52.35% 2.798% 9.47% 18.099%
ROA
-36.76% 7.228% -52.86% 4.191% -53.90% 2.407% -16.45% 16.694%
ROIC
-38.94% 7.287% -55.58% 4.085% -56.82% 2.397% -20.53% 17.150%
Net Profit Ratio
-17.07% 41.258% -23.03% 40.409% -15.46% 44.785% -2.58% 51.734%
Gross Income Ratio
-7.89% 72.901% -11.02% 72.688% -12.86% 72.950% -3.60% 79.805%
EBIT To Total Operating Revenue
-21.65% 40.324% -31.29% 37.958% -23.13% 43.716% -6.53% 53.955%
Period Costs Rate
16.93% 25.817% 25.66% 27.176% 6.00% 22.505% -6.75% 20.317%
Operating Expense Rate
14.04% 14.633% 22.74% 14.161% 11.31% 11.467% -9.27% 12.142%
Admini Expense Rate
4.66% 8.128% 4.38% 8.807% -26.19% 6.226% 29.08% 6.791%
Financial Expense Rate
-14.66% -6.696% -40.40% -7.536% -70.58% -6.998% -51.94% -5.868%
Recurrent Net Profit
-28.81% 268.01M -45.78% 151.01M -48.01% 86.9M 28.59% 554.47M
Operating Profit Ratio
-18.26% 47.019% -25.30% 45.505% -16.83% 50.707% -3.62% 59.927%
EBIT
-30.66% 276.83M -50.38% 149.41M -51.15% 88.59M 22.27% 595.13M
Solvency
Current Ratio
-33.58% 2.9414 -56.80% 2.7363 -38.37% 3.7473 -48.52% 3.5781
Quick Ratio
-35.47% 2.7322 -58.57% 2.5101 -40.32% 3.5016 -50.26% 3.3571
Debt Equity Ratio
-3.26% 22.222% 20.39% 19.654% 4.78% 17.565% 21.95% 18.118%
Shareholders Equity Without Minority Interests To Total Liabilities
3.32% 449.707% -16.99% 508.439% -4.58% 569.239% -18.01% 551.875%
Shareholders Equity Without Minority Interests To Interest Bear Debt
26.16% 4.79K% 50.25% 10.73K% -32.35% 6.48K% -10.46% 4.04K%
Long Debt To Working Capital
100.45% 0.0884 178.96% 0.1127 213.96% 0.0697 172.49% 0.0624
Growth Ability
Average Net Profit YOY Past Five Year
-- -- -- -- -- -- -- 0.336%
Sustainable Grow Rate
-36.96% 8.982% -52.26% 5.044% -53.86% 2.878% -24.67% 21.068%
Operating Capacity
Operating Cycle(D/T)
34.64% 289.8828 44.55% 310.1455 57.68% 304.6244 -1.66% 214.0144
Inventory Turnover Days(D/T)
13.19% 175.8385 20.50% 191.6933 30.97% 185.7969 -12.47% 145.3606
Accounts Receivable Turnover Days(D/T)
90.20% 114.0444 113.54% 118.4522 131.54% 118.8276 33.15% 68.6538
Inventory turnover Rate(T)
-11.65% 1.5356 -17.01% 0.939 -23.63% 0.4845 14.24% 2.4766
Accounts Receivable Turnover Rate(T)
-47.43% 2.3675 -53.17% 1.5197 -56.81% 0.7574 -24.90% 5.2438
Current Assets Turnover Rate(T)
23.58% 0.3774 9.97% 0.2449 -8.79% 0.1141 2.65% 0.5224
Total Assets Turnover Rate(T)
-23.73% 0.1752 -38.75% 0.1037 -45.44% 0.0538 -14.22% 0.3227
Fixed Assets Turnover Rate(T)
-55.47% 0.9677 -59.38% 0.6094 -55.83% 0.3843 -21.39% 3.0674
Equity Turnover Rate(T)
-22.99% 0.2107 -36.98% 0.1234 -44.48% 0.0634 -14.59% 0.3763
Cash Position
Free Cash Flow
-52.83% 120.05M 338.44% 581.93M -83.81% 30.8M -613.38% -335.53M
Net Profit Cash Cover
-4.85% 116.830% 19.86% 116.616% -20.50% 117.195% 4.17% 93.084%
Operating Revenue Cash Cover
2.24% 105.683% 19.26% 116.683% 8.44% 138.207% -8.24% 84.859%
Operating Cash In To Assets
-39.78% 8.450% -43.48% 4.889% -63.35% 2.822% -12.94% 15.543%
Dividend Ability
Dividend Per Share
-34.48% 0.19 -34.48% 0.19 0.00% 0.29 0.00% 0.29
Dividend Paid Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Retained Earning Ratio
0.00% 100.000% 0.00% 100.000% 0.00% 100.000% 43.09% 100.000%
Capital Structure
Debt Assets Ratio
-2.67% 18.182% 17.04% 16.426% 4.07% 14.940% 18.58% 15.339%
Current Assets To Total Assets
-36.50% 45.642% -48.59% 37.590% -40.10% 46.985% -40.25% 47.279%
Non Current Assets To Total Assets
93.25% 54.358% 132.21% 62.410% 145.83% 53.015% 152.59% 52.721%
Fix Assets Ratio
56.84% 21.970% 27.78% 20.084% -10.24% 14.140% 111.23% 13.836%
Interest Bearing Debt To Total Capital
-20.35% 2.046% -33.18% 0.923% 47.06% 1.519% 11.38% 2.416%
Yield Quality
Net Income From Value Changes To Total Profit
48.99% 1.262% 86.08% 1.443% 77.96% 1.121% 1.48% 0.777%
Recurrent Net Profit To Net Profit
-3.00% 94.623% -2.47% 94.942% -3.23% 95.746% 0.91% 97.167%
Dupont Analysis
Equity Multipler_DuPont
0.99% 120.286% 2.89% 118.947% 1.74% 117.854% -0.42% 116.620%
Net Profit of Parent Company OwnersTo Net Profit_DuPont
0.07% 100.066% 0.03% 100.034% 0.01% 100.007% 0.02% 100.018%
Net Profit To Total Operating Revenue_DuPont
-17.07% 41.258% -23.03% 40.409% -15.46% 44.785% -2.58% 51.734%
Net Profit To Total Profit_DuPont
1.08% 87.746% 2.53% 88.769% 1.64% 88.308% 0.33% 86.454%
Total Profit To EBIT_DuPont
4.72% 116.606% 9.25% 119.927% 8.20% 116.009% 3.88% 110.908%
EBIT To Total Operating Revenue_DuPont
-21.65% 40.324% -31.29% 37.958% -23.13% 43.716% -6.53% 53.955%
Currency Unit
CNYCNYCNYCNY

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company was founded in 2001, specializing in veterinary biological products research and development, production, sales and animal epidemic prevention technical services, the company is awarded by the National Development and Reform Commission "National High-tech industrialization demonstration Project" key high-tech enterprises. The company is a biomedical company specializing in the research and development, production and sales of veterinary biological products and animal epidemic prevention technical services, the main products are non-state compulsory immunization pig vaccines and poultry vaccines. The company's main products are non-state compulsory immunization pig vaccines and poultry vaccines. Enterprise honors: the second prize of the National Science and Technology Progress Award, the first prize of Hubei Science and Technology Progress Award, and the national key new products.
CEO: Huanchun Chen
Market: --
Listing Date: 09/22/2020
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist